Xerostomia Therapeutics Market (2026 - 2033)

Xerostomia Therapeutics Market Summary

The global xerostomia therapeutics market size was valued at USD 2.2 billion in 2025 and is projected to grow from USD 2.3 billion in 2026 to USD 3.0 billion by 2033, at a CAGR of 3.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 39.3% in 2025. The increasing adoption of chemotherapy and radiotherapy in cancer treatment coupled with the growing use of prescribed medications are among the key factors expected to boost the market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Xerostomia refers to a condition of oral dryness mainly caused by reduced saliva production. This condition may lead to a sensation of dryness in the mouth, oral burning, difficulty in swallowing, and reduction or loss of taste. Chemotherapy and radiation damage the salivary gland and cause dry mouth. Chemotherapy is the most common form of treatment for cancer patients provided by oncologists and medical practitioners. Xerostomia is usually a side effect of medication, head & neck radiation therapy, and chemotherapy, and it may also be caused due to Sjogren’s syndrome. The American Cancer Society estimates that 3.5 million women live with breast cancer in the U.S., as of January 1, 2016. Among women with stage IV breast cancer, 48% receive radiation and/or chemotherapy.

To learn more about this report, Download Free Sample Report

The easy availability of cost-effective medications is one of the key drivers of the market. Products include sugar-free gum, lozenges, toothpaste, oral-adhering discs, patches, and melts, as well as oral rinses. These products have reasonable reimbursement policies and have a price range of USD 10 to USD 90. For instance, the Ontario Ministry of Health and Long-Term Care provides funds to patients with radiation-induced xerostomia undergoing treatment with the drug, Salagen, under the Exceptional Access Program (EAP). An increase in the use of prescription medications is expected to positively affect the market growth. According to the National Institute of Dental and Craniofacial Research, more than 400 medications may cause xerostomia.

Prescription medicines such as antidepressants, antihypertensives, sedatives, antiparkinson, antiemetics, and antipsychotics affect the salivary gland and cause xerostomia. The increasing prevalence of diseases such as Parkinson’s disease, hypertension, and diabetes leads to the use of prescription drugs, thus causing the condition of dry mouth.

Market Dynamics

The xerostomia therapeutics market is experiencing steady growth due to the increasing prevalence of dry mouth associated with Sjögren’s syndrome, cancer radiotherapy, diabetes, and the growing use of medications that impair salivary gland function. The market is characterized by continued demand for salivary stimulants, saliva substitutes, oral rinses, gels, and sprays that provide symptomatic relief and improve oral health outcomes. Growing awareness among healthcare providers regarding the long term complications of untreated xerostomia, including dental caries, periodontal disease, and oral infections, is supporting earlier diagnosis and treatment adoption. Advances in oral care formulations and ongoing research focused on improving salivary gland function are expanding available treatment options for patients with chronic xerostomia. In addition, the increasing elderly population, which is more susceptible to medication induced dry mouth and age related salivary gland dysfunction, continues to support treatment demand. Rising incidence of autoimmune disorders and head and neck cancers is further contributing to the need for effective therapeutic interventions, supporting continued development activity across the xerostomia therapeutics market.

Analyst Perspective

The xerostomia therapeutics market is witnessing consistent growth driven by the increasing incidence of Sjögren’s syndrome, head and neck cancers requiring radiotherapy, diabetes, and age related salivary gland dysfunction. Treatment utilization remains centered on salivary stimulants, saliva substitutes, and oral care products that help manage chronic dry mouth symptoms and reduce associated oral health complications. The market is gradually shifting beyond symptomatic management as research institutions and biotechnology companies advance regenerative cell therapies and gene based approaches designed to restore salivary gland function. Increasing awareness among healthcare providers regarding the impact of xerostomia on patient quality of life and oral health is supporting earlier diagnosis and treatment intervention. Continued investment in innovative therapies and supportive care solutions is expected to broaden treatment options and contribute to the long term development of the xerostomia therapeutics market..

Type Insights

Based on type, the OTC segment led the market with the largest revenue share of 58.3% in 2025. The dominance is owing to its wide variety & availability, safety & efficacy, availability of limited branded drugs, and low pricing of products. OTC products are the first-line treatment for xerostomia. Most xerostomia can be dealt with OTC products without any complications. In severe cases, prescription drugs are utilized. With proper care and medication, it can be managed and controlled and any further complications can be avoided.

Product Insights

Based on product, the salivary stimulants segment led the market with the largest revenue share of 35.4% in 2025. Salivary stimulants are substances that can increase the production of saliva. They can be further classified as pharmacological (acts on the nervous system) and non-pharmacological (acts on taste buds or chewing muscles). They are available in various forms such as mints, sugar-free chewing gums, sprays, and lozenges. In November 2018, 3M launched Xerostomia Relief Spray, which relieves the mouth for up to 4 hours by moistening and lubricating mucosa. In September 2021, ICPA Health Products Ltd., launched Wet Mouth, a sodium carboxymethyl cellulose-based saliva substitute for treating xerostomia, which helps reduce surface abrasion.

To learn more about this report, Download Free Sample Report

The dentifrices segment is expected to grow at the fastest CAGR of 4.9% over the forecast period. These are special teeth cleaning agents, powders, or pastes, which help in reducing dry mouth by excluding irritants causing dry mouth. GC America Inc.’s MI Paste and MI Paste Plus are products that can be applied to the teeth to help stimulate saliva production as well as restore healthy components of saliva such as calcium and phosphate.

Regional Insights

North America dominated the xerostomia therapeutics market with the largest revenue share of 39.3% in 2025. Key factors contributing toward dominance are the increasing prevalence of xerostomia and other dry mouth-associated diseases such as Sjogren’s syndrome, and rheumatoid arthritis, coupled with an increase in dry mouth awareness initiatives. The Sjogren’s Foundation has taken initiatives to spread awareness of Sjogren’s syndrome by creating the April is Sjogren’s Awareness Month campaign.

To learn more about this report, Download Free Sample Report

U.S. Xerostomia Therapeutics Market Trends

The xerostomia therapeutics market in the U.S. held the largest share in the North America region in 2025. 

Asia Pacific is anticipated to grow at the fastest CAGR of 5.0% over the forecast period due to rising healthcare spending, an increase in awareness-raising campaigns, and an increase in the prevalence of diabetes, cancer, and Parkinson's disease. According to a study by NIH, the incidences of Parkinson’s disease increased by 202.22%, 204.06%, 164.21%, and 67.93% in East Asia, South Asia, Southeast Asia, and Central Asia, respectively, from 1990 to 2019.

Key Companies & Market Share Insights

Key players focus on the development of their product portfolio, acquisition of emerging players, and distribution agreements to increase their geographical presence. As per the article published in June 2023, MeiraGTx, a clinical-stage gene therapy company, is developing AAV-AQP1, which is in phase II for the treatment of xerostomia. It is for xerostomia treatment caused by the use of ionizing radiation in the treatment of neck & head cancer and Sjogren's syndrome-related xerostomia. Some prominent players in the global xerostomia therapeutics market include:

Key Xerostomia Therapeutics Companies

The following key companies have been profiled for this study on the xerostomia therapeutics market

• GlaxoSmithKline plc

• Church & Dwight Co., Inc.

• Colgate-Palmolive Company

• Hikma Pharmaceuticals PLC

• Pendopharm

• Sun Pharmaceuticals Industries Ltd.

• Lupin Pharmaceuticals, Inc.

• Pfizer, Inc.

• Parnell Pharmaceuticals, Inc.

• Acacia Pharma

• OraCoat

Global Xerostomia Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global xerostomia therapeutics market report based on product, type, and region:

To learn more about this report, Download Free Sample Report

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • OTC

  • Prescription

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Salivary Stimulants

  • Salivary Substitutes

  • Dentifrices

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The xerostomia therapeutics market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each xerostomia therapeutics segment quantified using the revenue-capture definitions in the table below.

Estimation Model 

The xerostomia therapeutics market was estimated using a commodity flow and revenue-based market analysis approach. The methodology began with the identification of key manufacturers and commercially available therapies used for the management of xerostomia. Major product categories, including salivary stimulants, salivary substitutes, dentifrices, oral sprays, mouth rinses, gels, and prescription secretagogues, were benchmarked based on annual sales, prescription volumes, pricing, distribution channels, and geographic presence. Revenue generated from leading products was assessed using company annual reports, investor presentations, regulatory filings, healthcare databases, pharmacy sales records, and industry publications. Product level revenues were aggregated to estimate market revenues across over the counter and prescription segments.

The market estimates were further validated through an assessment of the xerostomia patient population associated with Sjögren’s syndrome, head and neck cancer radiotherapy, medication induced dry mouth, diabetes, and other chronic conditions. Treatment utilization rates, prescription patterns, and product consumption trends across hospitals, retail pharmacies, dental clinics, and online pharmacies were analyzed to determine demand side dynamics. Data triangulation was performed by comparing manufacturer revenues, product sales volumes, and patient treatment rates to ensure consistency across market estimates. Forecast projections incorporated disease prevalence trends, aging population growth, product innovation, treatment adoption rates, and the development of regenerative and gene based therapies.

Delivered Customizations

This report has been delivered with the following In-depth customizations